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The inner ear is a complex and delicate structure composed of 
the cochlea and the vestibular system. To maintain normal 
auditory function, strict homeostasis of the inner ear is needed. 
A proper immune response against infection, thus, is crucial. 
Also, since excessive immune reaction can easily damage the 
normal architecture within the inner ear, the immune response 
should be fine regulated. The exact mechanism how the inner 
ear’s immune response, specifically the innate immunity, is 
regulated was unknown. Recently, we reported a protein selec-
tively localized in the inner ear during bacterial infection, 
named cochlin, as a possible mediator of such regulation. In 
this review, the immunological function of cochlin and the 
mechanism behind its role within inner ear immunity is sum-
marized. Cochlin regulates innate immunity by physically en-
trapping pathogens within scala tympani and recruiting innate 
immune cells. Such mechanism enables efficient removal of 
pathogen while preserving the normal inner ear structure from 
inflammatory damage. [BMB Reports 2020; 53(9): 449-452]
INTRODUCTION
The inner ear is a complex and delicate structure comprising 
the cochlea and the vestibular system. The cochlea, which 
enables hearing in humans, must be maintained in a strict 
homeostasis to function (1). Several congenital and acquired 
defects in the cochlea cause hearing loss (2-4). Although the 
incidence does not frequently occur, infective disorders, e.g. 
otitis media, labyrinthitis, can irreversibly damage the core 
auditory structure, named the organ of Corti, and cause 
life-long hearing loss (5). A proper immune response against 
infection, thus, is crucial for preserving the auditory function. 
The inner ear had long been considered an ‘immune-privile-
ged’ structure with the eyes and brain. However, recent 
studies revealed that immune cells, specifically macrophages, 
are within the mesenchymal region of the cochlea, namely the 
stria vascularis and the spiral ligament in the lateral wall (6-8). 
Such immunity can thus protect the inner ear from pathogens 
as well as from the endogenous toxins. However, since exces-
sive immune reaction can easily damage the normal archi-
tecture within the inner ear, the immune response should be 
fine regulated. Recently, we reported a protein selectively 
localized in the inner ear during bacterial infection, named 
cochlin, as a possible mediator of such regulation (8). In this 
review, the immunological function of cochlin and the mecha-
nism behind its role within the inner ear immunity are sum-
marized. 
COCHLIN: WHAT IS KNOWN?
Discovery
Cochlin, as implied by its name, is abundantly expressed in 
the cochlea and the vestibule of the inner ear; additionally, in 
the lymphoid organs including the lymph and spleen (9, 10). 
Robertson et al. reported the novel Coch gene, which encodes 
cochlin, and its selective expression in the inner ear of humans. 
They also found that the mutation of the Coch gene is linked 
with the DFNA9 syndrome, an autosomal-dominant disease of 
the ear that causes late-onset neurosensory degeneration of the 
inner ear (9, 10). Such association with the hereditary hearing 
disorder and its selective expression led to a speculation that 
cochlin may play a critical role in auditory function.
Structure
The structure of cochlin is divided into two parts, the LCCL 
domain at the N-terminus and the two vWFA domains at the 
other end (Fig. 1) (10). The LCCL domain, commonly present 
in the Limulus Factor C, cochlin and lgl1 protein, comprises 
multiple beta strands and an alpha helix (11). The functional 
role of this domain had been postulated by researchers that it 
may be related to the LPS-binding of the Factor C protein (11, 
12). However, Py et al. found that LCCL domain serves as a 
regulator of the innate immunity and its function is not 
restricted to the LPS (13). Additionally, most of the mutations 
linked with DFNA9 syndrome were found in the LCCL do-
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Fig. 1. The LCCL domain is cleaved from the splenic cochlin and secreted into the blood during infection. Cochlin comprises the LCCL 
domain at the N-terminus and the two vWFA domains at the C-terminus. The follicular dendritic cells in the spleen and the lymph nodes 
produce and secrete cochlin in the extracellular matrix called a conduit. Here, the vWFA domains bind with the collagen cores of the 
conduits making cochlins to stock within the conduits. During infection, the LCCL domain is cleaved from the intact cochlin by aggre-
canse 1 and secreted into the systemic circulation. The cleaved LCCL modulates innate immune response assisting bacterial clearance.
main, implying its defensive role in auditory preservation (11). 
The vWFA domain mediates cochlin’s adhesion with different 
components of the extracellular matrix (ECM) (14). Specifi-
cally, a previous study found that cochlin binds to the collagen 
bundle within the B-cell zone of the spleen via vWFA domains 
(13).
The two parts of cochlin are cleaved by a member of the 
metalloprotease family, named aggrecanase 1 (8, 13). Py et al. 
showed that the expression of Adamts-4 gene encoding aggre-
canase 1 is upregulated following the LPS injection in the spleen 
(13). Likewise, we showed the up-regulation of Adamts-4 gene 
in cochlea after the PAO1 infection (8). This cleavage enables 
the liberation of cleaved LCCL domain and initiates the 
subsequent immune responses. Since the mutated cochlin in 
DFNA9 patients showed reduced susceptibility to cleavage 
(15), this implies that the cleavage is the crucial step for 
cochlin function. 
Function
Previous research illuminated the role of splenic cochlin as the 
mediator of innate immunity (13). The study found that cochlin 
was specifically secreted by the follicular dendritic cells within 
the spleen and was stored in the surrounding ECM called a 
conduit. As a response to Pseudomonas aeruginosa (PA) infec-
tion, the expression of aggrecanase 1 increased and resulted in 
cleavage of the LCCL from the cochlin. The LCCL domain was 
then secreted into the blood and mediated the activity of 
innate immune cells. Until recently, the exact mechanism how 
the LCCL domain regulates innate immunity was unclear. 
However, the defect of innate immunity shown in Coch(−/−) 
mice highly suggested cochlin’s essential role in the immune 
system (13). Additionally, considering the selective expression 
of cochlin in the inner ear and the fact that the inner ear is 
separated from the systemic circulation by the blood-labyrin-
thine barrier (16), cochlin’s specific role within the inner ear 
remained a core question to be solved. Therefore, further 
study regarding the physiology behind LCCL domain’s action, 
especially within the inner ear, was required. 
COCHLIN, THE DUAL-ARMED IMMUNE-REGULATOR 
OF THE INNER EAR
We showed that the baseline auditory function between the 
wild type mice and Coch knock-out mice did not differ sig-
nificantly (8). However, following the PA infection, the Coch 
knock-out mice showed greater hearing loss compared to the 
wild type mice. Thus, we suggested that cochlin’s auditory 
protection may be linked to its anti-bacterial action. Also, we 
specified that cleaved LCCL domain is the mediator of such 
protective role. LCCL within the perilymph of ex vivo explants 
of the inner ear increased after infection and, more surpri-
singly, injection of LCCL to the Coch knock-out mice induced 
improvement in the hearing loss. 
We elucidated two main mechanisms by which LCCL relea-
sed in scala tympani regulates immune response (Fig. 2) (8). 
First, LCCL recruits innate immune cells by increasing the 
expression of pro-inflammatory cytokines such as IL-1 and 
IL-6. The infiltrations of neutrophils and macrophages were 
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Fig. 2. Cochlin is the dual-armed immune-regulator of the inner ear. The inner ear is a delicate structure enclosing the key auditory 
structure, organ of Corti. Since excessive immune reaction can easily damage the normal architecture, the immune response should be 
fine regulated in the inner ear. Cleaved cochlin LCCL mediates such regulation in two ways. First, it controls the range of inflammation 
by physically entrapping pathogens in a limited space. Second, it recruits innate immune cells allowing clearance of the pathogen. Such 
dual-armed regulation of immune response makes cochlin a crucial component in auditory preservation.
increased in the wild type mice, compared to those in the 
Coch knock-out mice. Specifically, the number of monocyte- 
derived macrophages distinsuished from resident macrophages 
based on morphology, significantly increased in the wild type 
mice. This implies that the recruitment of the innate immune 
cells within the blood vessels is facilitated by the LCCL. Addi-
tionally, we found that LCCL physically interacts with the pa-
thogen. Previous studies reported that LCCL do not directly 
interact with neither bacterial molecules such as LPS, pattern 
recognition peptidoglycans, nor the bacteria (13, 17). Our 
study also found that the viability of PA was not impacted by 
the addition of the recombinant LCCL peptide in vitro (8). 
However, by examining the growth of the bacteria on glass 
coverslips, we reported that the presence of LCCL markedly 
affects their growth pattern. Compared to the normal condition, 
the treatment of LCCL increased numbers of globular shaped 
colonies that co-localized with LCCL. Scanning electron micro-
scopic images additionally confirmed bacterial aggregation 
and entrapment. This physical interaction was also observed in 
the gram positive bacteria, e.g. Staphylococcus aureus, indicating 
the interaction is not mediated by the LPS. These two mecha-
nisms successfully explain how the immune response within 
inner ear is regulated in a way that prevents damage to the 
core auditory structure, or the organ of Corti. As most of the 
bacteria enters the inner ear through the round window, adja-
cent to the scala tympani, the initial immune response likely 
occurs within the scala tympani (5). Thus, physically containing 
the bacteria within the scala tympani while inducing innate 
immune cells’ recruitment is logical in preventing further 
progression of the infection to the scala media, wherein the 
organ of Corti lies.
CONCLUSION
In this review, we discussed the immunological role of the 
cochlin and how the innate immunity within the inner ear is 
delicately controlled by the cochlin. The LCCL domain is cleaved 
from the full-length cochlin by aggrecanase I after infection. 
The LCCL domain then acts as a systemic modulator of innate 
immunity by up-regulating the expression of pro-inflammatory 
cytokines such as IL-1 and IL-6. In the inner ear, the LCCL 
controls the range of inflammation by physically entrapping 
pathogens as well as inducing the recruitment of innate immune 
cells. In conclusion, cochlin, long known to be linked with 
auditory function, protects the core sensory structure from 
infection by inducing the needed immunity while limiting 
excessive inflammatory damage. 
Cochlin is currently studied in various areas of medicine. It 
is linked with glaucoma, autoimmune disease of the inner ear, 
as well as the DFNA9 syndrome mentioned above (18, 19). 
Since the exact mechanisms how such defects occur are 
elusive, further research must be conducted. The clinical use 
of cochlin is currently very limited. Ikezono et al. suggested 
the use of cochlin-tomoprotein, an isoform of cochlin, as an 
effective diagnostic tool for perilymphatic fistula based on its 
limited expression in the inner ear (20). Based on our findings, 
the clinical use of cochlin may expand further as a potential 
therapeutic for hearing loss from infection, e.g. chronic otitis 
media.
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